Analyser av WntResearch

WntResearch: Q3 cash position aligned with our expectations - Redeye

Redeye provides a note following WntResearch’s Q3 2024 report.

Redeye provides a comment on WntResearch’s update regarding the work in progress.

Redeye provides a longer note following WntResearch’s failed phase 2 study and CEO interview.

Redeye provides a brief comment on WntResearch’s initial phase 2 data.

Redeye provides an update following WntResearch’s Q2 report.

Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology.

WntResearch, som genomför en fas 2-studie med läkemedelskandidaten Foxy-5 för patienter som drabbats av cancer i tjocktarmen, har efter nya ...